FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
Online ISSN : 2185-4610
Print ISSN : 0016-2590
ISSN-L : 0016-2590
Review
Immunotherapy for esophageal squamous cell carcinoma: a review
Kosaku MimuraLeo YamadaDaisuke UjiieSuguru HayaseTakeshi TadaHiroyuki HanayamaAung Kyi Thar MinMasahiko ShibataTomoyuki MommaZenichiro SazeShinji OhkiKoji Kono
著者情報
ジャーナル オープンアクセス HTML

2018 年 64 巻 2 号 p. 46-53

詳細
抄録

Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.

著者関連情報
© 2018 The Fukushima Society of Medical Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
https://creativecommons.org/licenses/by-nc-sa/4.0/
次の記事
feedback
Top